uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs
Trinity Coll Dublin, Trinity Biomed Sci Inst, Sch Pharm & Pharmaceut Sci, Dublin, Ireland..ORCID iD: 0000-0003-0730-1829
Mylan Global Resp Grp, Sandwich, Kent, England..ORCID iD: 0000-0001-6210-8461
Univ Poitiers, CHU Poitiers, UFR Med Pharm, Inserm,U1070, Poitiers, France..
GlaxoSmithKline Medicines Res Ctr, Refractory Resp Inflammat DPU, Stevenage, Herts, England..
Show others and affiliations
2017 (English)In: Journal of Pharmaceutical Sciences, ISSN 0022-3549, E-ISSN 1520-6017, Vol. 106, no 9, p. 2234-2244Article in journal (Refereed) Published
Abstract [en]

The School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin hosted the "1st Workshop on Drug Transporters in the Lungs" in September 2016 to discuss the impact of transporters on pulmonary drug disposition and their roles as drug targets in lung disease. The workshop brought together about 30 scientists from academia and pharmaceutical industry from Europe and Japan and addressed the primary questions: What do we know today, and what do we need to know tomorrow about transporters in the lung? The 3 themes of the workshop were: (1) techniques to study drug transporter expression and actions in the lungs; (2) drug transporter effects on pulmonary pharmacokinetics-case studies; and (3) transporters as drug targets in lung disease. Some of the conclusions of the workshop were: suitable experimental models that allow studies of transporter effects are available; data from these models convincingly show a contribution of both uptake and efflux transporters on pulmonary drug disposition; the effects of transporters on drug lung PK is now better conceptualized; some transporters are associated with lung diseases. However, more work is needed to establish which of the available models best translate to the clinical situation.

Place, publisher, year, edition, pages
2017. Vol. 106, no 9, p. 2234-2244
Keywords [en]
absorption, computational ADME, efflux pumps, in vitro models, organic cation transporters, P-glycoprotein, peptide transporters, pulmonary delivery/absorption, ABC transporters, organic anion-transporting polypeptide transporters
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-344532DOI: 10.1016/j.xphs.2017.04.011ISI: 000417339900010PubMedID: 28416418OAI: oai:DiVA.org:uu-344532DiVA, id: diva2:1188419
Available from: 2018-03-07 Created: 2018-03-07 Last updated: 2018-03-07Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Fridén, Markus

Search in DiVA

By author/editor
Ehrhardt, CarstenBackman, PerFridén, Markus
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Journal of Pharmaceutical Sciences
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 25 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf